Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Mercaptopurine (also called 6-MP; 6-Thiohypoxanthine; 6-thiopurine; 6-mercaptopurine; Purinethol) is an approved anticancer medication used to treat malignancies. Furthermore, it is a commonly used immunosuppressive medication for the treatment of autoimmune disorders like rheumatoid arthritis, dermatological issues, inflammatory bowel disease, and rejection of solid organ transplants. By integrating thiopurine methyltransferase metabolites into DNA and RNA, it prevents the synthesis of purines from scratch.
Targets |
endogenous purines
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Enzyme Assay |
L6 myotubes are incubated for 24 hours in either DMSO control or 6-Mercaptopurine hydrate (6-MP), with treatments in serum-free DMEM during the last 3 hours. They are then incubated for an additional 60 minutes at 37°C in the presence or absence of 100 nM insulin. Subsequently, 50 μg of protein lysates are gathered, put through SDS-PAGE, and then immunoblotted using primary antibodies for an entire night at 4°C. Using Image J software, densitometric analysis of scanned films is used to finally quantify the proteins[2].
|
|
Cell Assay |
The Cell Viability Assay is used to quantify cell viability. 10,000 L6 skeletal muscle cells are seeded per well in 96-well plates, and after 7 days, the cells differentiate into myotubes. Before the assay, cells are treated for 24 hours with varying doses of 6-Mercaptopurine hydrate (6-MP). After 30 minutes of room temperature equilibration, 50 μL of Cell Titer-Glo reagent is added to each well, and the plates are mixed for 12 minutes on an orbital shaker to analyze the viability of the cells. A luminometer is used to measure luminosity[2].
|
|
Animal Protocol |
|
|
References |
|
Molecular Formula |
C5H4N4S
|
|
---|---|---|
Molecular Weight |
152.18
|
|
Exact Mass |
152.02
|
|
Elemental Analysis |
C, 39.46; H, 2.65; N, 36.82; S, 21.07
|
|
CAS # |
50-44-2
|
|
Appearance |
Solid powder
|
|
SMILES |
C1=NC2=C(N1)C(=S)N=CN2
|
|
InChi Key |
GLVAUDGFNGKCSF-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)
|
|
Chemical Name |
3,7-dihydropurine-6-thione
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 6.5712 mL | 32.8558 mL | 65.7117 mL | |
5 mM | 1.3142 mL | 6.5712 mL | 13.1423 mL | |
10 mM | 0.6571 mL | 3.2856 mL | 6.5712 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05811845 | Recruiting | N/A | Acute Lymphoblastic Leukemia | IRCCS Burlo Garofolo | July 30, 2022 | N/A |
NCT01503632 | Active Recruiting |
Behavioral: Behavioral Intervention Drug: Mercaptopurine |
Acute Lymphoblastic Leukemia | Children's Oncology Group | February 21, 2012 | Phase 3 |
NCT02046694 | Completed | Drug: Allopurinol | Acute Lymphoblastic Leukemia (ALL) |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
January 6, 2014 | Early Phase 1 |
NCT00648336 | Completed | Drug: Mercaptopurine 50 mg Drug: Purinethol® Tablets 50 mg |
Healthy | Mylan Pharmaceuticals Inc | November 2003 | Phase 1 |
NCT01324336 | Completed | Drug: 6-Mercaptopurine | Acute Lymphoblastic Leukemia | Children's Mercy Hospital Kansas City |
July 2011 | N/A |
Effects of 6-mercaptopurine (6-MP) on glucose transport activity and cell viability in L6 myotubes. Am J Physiol Endocrinol Metab . 2013 Nov 1;305(9):E1081-92. td> |
Effects of 6-MP on NR4A3 transcriptional activity and protein expression. Am J Physiol Endocrinol Metab . 2013 Nov 1;305(9):E1081-92. td> |
Effects of NR4A3 overexpression and 6-MP on glucose transport in L6 skeletal muscle cells. Am J Physiol Endocrinol Metab . 2013 Nov 1;305(9):E1081-92. td> |
Effects of NR4A3 knockdown and 6-MP on glucose transport in L6 skeletal muscle cells. Am J Physiol Endocrinol Metab . 2013 Nov 1;305(9):E1081-92. td> |